| Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification A Lopez-Guillermo, J Cid, A Salar, A Lopez, C Montalban, JM Castrillo, ... Annals of Oncology 9 (8), 849-855, 1998 | 345 | 1998 |
| Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria E Matutes, D Oscier, C Montalban, F Berger, E Callet-Bauchu, A Dogan, ... Leukemia 22 (3), 487-495, 2008 | 318 | 2008 |
| Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up✰ E Zucca, L Arcaini, C Buske, PW Johnson, M Ponzoni, M Raderer, ... Annals of oncology 31 (1), 17-29, 2020 | 262 | 2020 |
| Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group M Salido, C Baró, D Oscier, K Stamatopoulos, J Dierlamm, E Matutes, ... Blood, The Journal of the American Society of Hematology 116 (9), 1479-1488, 2010 | 228 | 2010 |
| Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry S Quijano, A López, J Manuel Sancho, C Panizo, G Debén, C Castilla, ... Journal of Clinical Oncology 27 (9), 1462-1469, 2009 | 224 | 2009 |
| R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. A Martín, E Conde, M Arnan, MA Canales, G Deben, JM Sancho, ... Ferrata Storti Foundation, 2008 | 212 | 2008 |
| Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets K Karube, A Enjuanes, I Dlouhy, P Jares, D Martín-García, F Nadeu, ... Leukemia 32 (3), 675-684, 2018 | 181 | 2018 |
| Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study A Salar, N Juanpere, B Bellosillo, E Domingo-Domenech, B Espinet, ... The American journal of surgical pathology 30 (10), 1274-1280, 2006 | 155 | 2006 |
| Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease E González Barca, E Domingo Domenech, FJ Capote, J Gómez Codina, ... Haematologica, 2007, vol. 92, num. 11, p. 1489-1494, 2007 | 146 | 2007 |
| Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation N Martinez, C Almaraz, JP Vaqué, I Varela, S Derdak, S Beltran, ... Leukemia 28 (6), 1334-1340, 2014 | 124 | 2014 |
| Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia E Gonzalez-Barca, A Fernandez-Sevilla, J Carratala, A Salar, J Peris, ... European Journal of Clinical Microbiology and Infectious Diseases 18, 539-544, 1999 | 119 | 1999 |
| Neurologic complications after allogeneic bone marrow transplantation. D Gallardo, C Ferra, JJ Berlanga, ED Banda, C Ponce, A Salar, E Alonso, ... Bone marrow transplantation 18 (6), 1135-1139, 1996 | 108 | 1996 |
| Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study A Salar, I Avivi, B Bittner, R Bouabdallah, M Brewster, O Catalani, ... Journal of Clinical Oncology, 2014 | 106 | 2014 |
| Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the … A Salar, E Domingo‐Domenech, C Estany, MA Canales, F Gallardo, ... Cancer 115 (22), 5210-5217, 2009 | 105 | 2009 |
| Risk stratification for S plenic M arginal Z one L ymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy … C Montalbán, V Abraira, L Arcaini, E Domingo‐Domenech, ... British journal of haematology 159 (2), 164-171, 2012 | 103 | 2012 |
| A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome G Clot, P Jares, E Gine, A Navarro, C Royo, M Pinyol, D Martín-Garcia, ... Blood, The Journal of the American Society of Hematology 132 (4), 413-422, 2018 | 97 | 2018 |
| Validation of the NCCN‐IPI for diffuse large B‐cell lymphoma (DLBCL): the addition of β2‐microglobulin yields a more accurate GELTAMO‐IPI C Montalbán, A Díaz‐López, I Dlouhy, J Rovira, A Lopez‐Guillermo, ... British Journal of Haematology 176 (6), 918-928, 2017 | 97 | 2017 |
| Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma B Espinet, I Salaverria, S Beà, N Ruiz‐Xivillé, O Balagué, M Salido, ... Genes, Chromosomes and Cancer 49 (5), 439-451, 2010 | 96 | 2010 |
| Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma WH Wilson, JEC Bromberg, M Stetler-Stevenson, SM Steinberg, ... haematologica 99 (7), 1228, 2014 | 91 | 2014 |
| Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens A Salar, J Sierra, M Gandarillas, MD Caballero, J Marin, JJ Lahuerta, ... Bone marrow transplantation 27 (4), 405-412, 2001 | 89 | 2001 |
